Trastuzumab Emtansine provides a HER2-targeting antibody-drug conjugate (ADC) for cancer and oncology research. It combines trastuzumab with the maytansinoid payload DM1, specifically supporting studies of HER2-targeted cytotoxicity, ADC mechanisms, and targeted drug delivery.
Key Features and Benefits
- HER2-Targeting ADC: Combines the HER2-directed monoclonal antibody trastuzumab with the cytotoxic payload DM1.
- DM1 Payload: Contains a maytansinoid microtubule inhibitor that specifically supports investigation of ADC-mediated cytotoxic mechanisms.
- HER2 Recognition: Supports research specifically involving HER2 expression, antibody binding, internalization, and targeted cellular delivery.
- Stable Linker: Uses a non-cleavable thioether linker to connect trastuzumab with the DM1 payload.
- Targeted Payload Delivery: Supports investigation of antibody-mediated delivery of DM1 to HER2-expressing cancer cells.
- Microtubule Disruption: DM1 interferes with microtubule function, specifically supporting studies of payload-dependent cellular responses.
- HER2 Cancer Research: Provides a well-characterized ADC platform for studying HER2-positive cancer models.
Applications
- HER2-Positive Cancer Research: Supports studies involving cancer models with elevated HER2 expression.
- Breast Cancer Research: Useful for investigating HER2-targeted mechanisms in HER2-positive breast cancer models.
- ADC Research: Supports studies of antibody targeting, internalization, payload delivery, and cytotoxic activity.
- HER2 Research: Useful for investigating HER2 expression, receptor targeting, and antibody-mediated cellular responses.
- Targeted Drug Delivery: Supports research into antibody-mediated delivery of maytansinoid payloads.
- Cell-Based Cancer Assays: Especially useful for evaluating HER2-dependent binding, internalization, and cellular responses.
- Mechanism-of-Action Studies: Supports investigation of HER2 targeting and DM1-mediated microtubule disruption.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Trastuzumab Emtansine combines HER2-directed antibody targeting with the microtubule-disrupting DM1 payload and specifically supports HER2-positive cancer, breast cancer, ADC, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
